ReviewFrontiers in pharmacology2026
Toward adaptive therapeutic timing: integration of mechanistic pharmacology and artificial intelligence in precision dosing.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Artificial intelligence (AI) is reshaping the dosing of medication. It is shifting practice from fixed schedules to flexible timing that better reflects the needs of individual patients. This review synthesizes recent work in which AI identifies improved windows for drug delivery. It spans multiple time horizons, ranging from minute-by-minute infusion control to regimen planning over weeks or months. These approaches integrate population pharmacokinetic modeling with machine learning and reinforcement learning. Each component serves a distinct purpose. Together, they can recommend the dose timing, adjust dosing intervals, and indicate when a planned treatment pause may be appropriate. The models link these recommendations to the physiological rhythms and current disease status of patients, so timing becomes a defined part of the dosing strategy rather than a simple clock-based rule. Recent advances cluster into three directions. First, reinforcement learning supports sequential dosing decisions in long-term therapies, where early choices shape later outcomes. Second, AI enables chronotherapy by aligning drug delivery with daily circadian biology. Third, hybrid models improve exposure prediction, which supports more accurate interval personalization for individual patients. However, key limitations remain. Many models show limited generalizability across clinical settings, and many methods still require rigorous clinical validation. Even with these constraints, the trajectory is consistent. AI is positioned to move therapeutic timing from a static calendar task to an adaptive, patient-centered element of precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.